Ayta I.A., McKinlay J.B., Krane R.J. The likely worldwide increase in erectile dysfunction between 1995. and 2025. and some possible policy consequences // BJU Int. - 1999. - Vol. 84. - P. 50-56.
Feldman H.A., Goldstein I Hatzichristou D.G. et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study // J. Urol. - 151. - P. 54-61.
Jackson G., Rosen R.C., Kloner R.A. et al. The second Princeton Consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine // J. Sex. Med. - 2006. - Vol. 3. - P. 28-36.
Jackson G. Prevention of cardiovascular disease by the early identification of erectile dysfunction // Int. J. Impot. Res. - 2008. - Vol. 20: s9-s14.
Nemec E.D., Mansfield L., Kennedy J.W. Heart rate and blood pressure responses during sexual activity in normal males // Am. Heart J. -
1976. - Vol. 92. - P. 274-277.
Bohlen J.G., Held J.P., Sanderson M.O. et al. Heart rate, rate-pressure product and oxygen uptake during four sexual activities // Arch. Intern. Med. - 1984. - Vol. 144. - P. 1745-1748.
Garcia-Barreto D., Sin-Chesa C., Revas-Estany E. et al. Sexual intercourse in patients who have had a myocardial infarction //
J. Cardiopulm. Rehabil. - 1986. - Vol. 6. - P. 324-328.
Jackson G. Sexual intercourse and angina pectoris // Int. Rehabil. Med. - 1981. - Vol. 3. - P. 35-37.
Jackson G., Hutter A. Cardiovascular issues in male and female sexual dysfunction. In Porst H, Buvat J (eds.) Standard Practice in Sexual Medicine, 2006. Oxford: Blackwell Publishing, pp.376-386.
Cheitlin M.D. Sexual activity and cardiac risk // Am. J. Cardiol. - 2005. - Vol. 96(Suppl). - P. 24M-28M.
Muller J.E., Mittleman M.A, Maclure M. et al. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators // JAMA. - 1996. - Vol. 275. - P. 1405-1409.
Moller J., Ahlbom A., Hulting J. et al. Sexual activity as a trigger of myocardial infarction. A case- crossover analysis in the Stockholm Heart Epidemiology Programme (SHEEP) // Heart. - 2001. - Vol. 86.
P. 387-390.
Drory Y. Sexual activity and cardiovascular risk // Eur. Heart J. - 2002. - Vol. 4(Suppl.H). - P. H13-H18.
Drory Y., Shapira I., Fisman E.Z. et al. Myocardial ischaemia during sexual activity in patients with coronary artery disease // Am. J. Cardiol. - 1995. - Vol. 75. - P. 835-837.
Jackson G., Padley S. Erectile dysfunction and silent coronary artery disease: abnormal computed tomography coronary angiogram in the presence of normal exercise ECGs // Int. J. Clin. Prac. - 2008. - Vol. 62. - P. 973-976.
Solomon H., Man J.W., Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator // Heart. - 2003. - Vol. 89. - P. 251-253.
Vlachopoulos C., Rokkas K., Ioakeimidis N. et al. Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links // Eur. Urol. - 2007. - Vol. 52. - P. 1590-1600.
Burchardt M., Burchardt T., Baer L. et al. Hypertension is associated with severe erectile dysfunction // J. Urol. - 2000. - Vol. 164. -
P. 1188-1191.
Guiliano F.A., Leriche A., Jaudinot E.O. et al. Prevalence of erectile dysfunction among 7689. patients with diabetes or hypertension, or both // Urology. - 2004. - Vol. 64. - P. 1196-1201.
Rosen R.C., Fisher W.A., Eardley I. et al. The multinational Men’s Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population // Curr. Med. Res. Opin. - 2004. - Vol. 20. - P. 607-617.
Solomon H., Samarasinghe Y.P., Feher M.D. et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients // Int. J. Clin. Pract. - 2006. - Vol. 60. - P. 141-145.
Desouza C., Parulkar A., Lumpkin D. et al. Acute and prolonged effect of sildenafil on brachial artery flow- mediated dilatation in type 2.
diabetes // Diabetes Care. - 2002. - Vol. 25. - P. 1336-1339.
Kirby M., Jackson G., Betteridge J. et al. Is erectile dysfunction a marker for cardiovascular disease? //
Int. J. Clin. Pract. - 2001. - Vol. 55. - P. 614-618.
Montorsi P., Montorsi F., Schulman CC. Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder? // Eur. Urol. - 2003. - Vol. 44. - P. 352-354.
Montorsi F., Briganti A., Salonia A. et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300. consecutive patients with acute chest pain and angiographically documented coronary artery disease // Eur. Urol. - 2003. - Vol. 44. - P. 360-365.
Pritzker M.R. The penile stress test: a window to the heart of man // Circulation. - 1999. - Vol. 100. - P.3751.
Kawanishi Y., Lee K.S., Kimura K. et al. Screening of ischemic heart disease with cavernous artery blood flow in erectile dysfunction patients // Int. J. Impot. Res. - 2001. - Vol. 13. - P. 100-103.
Speel T.G., van Langen H., Meuleman E.J. The risk of coronary heart disease in men with erectile dysfunction // Eur. Urol. - 2003. - Vol. 44. - P. 366-371.
Roumeguere T., Wespes E., Carpentier Y. et al. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk // Eur. Urol. - 2003. - Vol. 44. - P. 355-359.
Gazzaruso C., Giordanetti S., De Amici E. et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2. diabetic patients // Circulation. - 2004. -
Vol. 110. - P. 22-26.
Thompson I.M., Tangen C.M. et al. Erectile dysfunction and subsequent cardiovascular disease // JAMA.
2005. - Vol. 294. - P. 2996-3002.
Ponholzer A., Temml C., Obermayr R. et al. Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke? // Eur. Urol. - 2005. - Vol. 48. - P. 512-518.
Schouten B.W., Bohnen A.M., Bosch J.L. et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study // Int. J. Impot. Res. -
2008. - Vol. 20. - P. 92-99.
Hodges L.D., Kirby M., Solanki J. et al. The temporal relationship between erectile dysfunction and cardiovascular disease // Int. J. Clin. Pract. - 2007. - Vol. 61. - P. 2019-2025.
Montorsi P., Ravagnani P.M., Galli S. et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial // Eur. Heart J. - 2006. - Vol. 27. - P. 2632-2639.
Jackson, G., Betteridge J., Dean J. et al. A systematic approach to erectile dysfunction in the cardiovascular patient: a Consensus Statement - update 2002 // Int. J. Clin. Pract. - 2002. - Vol. 56. - P. 663-671.
Kostis J.B., Jackson G., Rosen R. et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference) // Am. J. Car-diol. - 2005. - Vol. 96. - P. 313-321.
Bacon C.G., Mittleman M.A., Kawachi I. et al. A prospective study of risk factors for erectile dysfunction // J. Urol. - 2006. - Vol. 176. -
P. 217-221.
Blanker M.H., Bohnen A.M., Groeneveld F.P. et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study // J. Am. Geriatr. Soc. - 2001. - Vol. 49. - P. 436-442.
Holden C.A., McLachlan R.I., Pitts M. et al. Men in Australia Telephone Survey (MATeS): a national survey of the reproductive health and concerns of middle-aged and older Australian men // Lancet. - 2005. - Vol. 366. - P. 218-224.
Esposito K., Giugliano F., Di Palo C. et al. Effect of lifestyle changes on erectile dysfunction in ovese men: a randomized controlled trial // JAMA. - 2004. - Vol. 291. - P. 2978-2984.
Laurmann E.O., Nicolosi A., Glassere D.B. et al. Sexual problems among women and men aged 4080 years: Prevalence and correlates indentified in the Global Study of Sexual Attitudes and Behaviour // In.t J. Impot. Res. - 2005. - Vol. 17. - P. 39-57.
Juenemann K.P., Lue T.F., Luo J.A. et al. The effect of cigarette smoking on penile erection // J. Urol. - 1997. - Vol. 138. - P. 438-441.
Esposito K., Giugliano F., Martedi E. et al. High proportions of erectile dysfunction in men with the metabolic syndrome // Diabetes Care. -
2005. - Vol. 28. - P. 1201-1203.
Kupelian V., Shabsigh R., Arauio A.B. et al. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study // J. Urol. - 2006. - Vol. 176. - P. 222226.
Makhsida N., Shah J., Yan G. et al. Hypogonadism and metabolic syndrome: implications for testosterone therapy // J. Urol. - 2006. - Vol. 174. - P. 827-834.
Esposito K., Ciotola M., Giugliano F. et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome // Int. J. Impot. Res. - 2006. - Vol. 18. - P. 405-410.
Jackson G. Phosphodiesterase 5. inhibition: effects on the coronary vasculature // Int. J. Clin. Pract. -
- Vol. 55. - P. 183-188.
Jackson G., Benjamin N., Jackson N. et al. Effects of sildenafil citrate on human hemodynamics // Am. J. Cardiol. - 1999. - Vol. 83. - P. 13C-20C.
Giuliano F. Phosphodiesterase type 5. inhibition in erectile dysfunction: an overview // Eur. Heart J. -
- Vol. 4(Suppl.H). - P. H7-H12.
Jackson G., Martin E., McGing E. et al. Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5. inhibitor use in stable coronary disease patients with erectile dysfunction // J. Sex. Med. - 2005. - Vol. 2. - P. 513-516.
Jackson G., Montorsi P., Cheitlin M.D. Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective // Urology. - 2006. - Vol. 68(Suppl.3A). - P. 47-60.
Fox K.M., Thadani U., Ma P.T. et al. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina // Eur. Heart. J. - 2003. - Vol. 24. - P. 2206-2212.
Herrmann H.C., Chang G., Klugherz B.D. et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease // N. Eng. J. Med. - 2000. - Vol. 342. - P. 1622-166.
Kloner R. Erectile dysfunction and hypertension // Int. J. Impot. Res. - 2007. - Vol. 19. - P. 296-302.
Webster L.J., Michelakis E.D., Davis T. et al. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial // Arch. Intern. Med. - 2004. - Vol. 164. - P.514-520.
Jackson G., Kloner R.A, Costigan T.M. et al. Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events // J. Sex. Med. - 2004. - Vol. 1. - P. 161-167.
Kloner R.A., Jackson G., Hutter A.M. et al. Cardiovascular safety update of Tadalafil: a retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing // Am. J. Cardiol. - 2006. - Vol. 97. - P. 1778-1784.
Brock G.B., McMahon C.G., Chen K.K. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses // J. Urol. - 2002. - Vol. 168. - P. 1332-1336.
McMahon C.G. Treatment of erectile dysfunction with chronic dosing of tadalafil // Eur. Urol. - 2006. - Vol. 50. - P. 215-217.
Thadani U., Smith W., Nash S. et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5. inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease // J. Am. Coll. Cardiol. - 2002. -
Vol. 40. - P. 2006-2012.
Zumbe J., Porst H., Sommer F. et al. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study // Eur. Urol. - 2008. - Vol. 54. - P. 204-210.
Porst H., Rosen R., Padma-Nathan H. et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5. inhibitor, in patients with erectile dysfunction: the first at-home clinical trial // Int. J. Impot. Res. - 2001. - Vol. 13. - P. 192-199.
Kloner R.A. Cardiovascular effect of the 3. phosphodiesteras-5. inhibitors approved for the treatment of erectile dysfunction // Circulation. -
2004. - Vol. 110. - P. 3149-3155.
Uthayathas S. Versatile effects of sildenafil: recent pharmacological applications // Pharmacological. Reports. - 2007. - Vol. 59. - P. 150-163.
Linet O.I., Ogrinc F.G. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group // N. Engl. J. Med. - 1996. - Vol. 334. - P. 873-877.
Padma-Nathan H., Hellstrom W.J., Kaiser F.E. et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group // N. Engl. J. Med.
1997. - Vol. 336. - P. 1-7.
Cookson M.S., Nadig P.W. Long-term results with vacuum constriction device // J. Urol. - 1993. - Vol. 149. - P. 290-294.
Basaria S., Dobs A.S. Testosterone making an entry into the cardiometabolic world // Circulation. - 2007.
Vol. 116. - P. 2658-2661.
Alexandersen P., Christiansen C. The aging male: testosterone deficiency and testosterone replacement. An up-date // Atherosclerosis. -
2004. - Vol. 173. - P. 157-169.
Allan C.A., Strauss B.J.G., McLachlan RI. Body composition, metabolic syndrome and testosterone in aging men // Int. J. Impot. Res. -
- Vol. 191. - P. 448-457.
Grundy S.M. Obesity, metabolic syndrome and cardiovascular disease // J. Clin. Endocrinol. Metab. - 2004. - Vol. 89. - P. 2595-2600.
Shabsigh R., Arver S., Channer K.S. et al. The triad of erectile dysfunction, hypogonadism, and the metabolic syndrome // Int. J. Clin. Pract. - 2008. - Vol. 62. - P. 672-674.
Tenover J.S. Effects of testosterone supplementation in the aging male // J.              Clin. Endocrinol.              Metab. -
1992. - Vol. 25. - P. 1092-1098.
Channer K.S., Jones T.H. Cardiovascular effects of testosterone: implications of the "male menopause"? // Heart. - 2003. - Vol. 89. - P. 121-122.
Rosano G.M.C., Leonardo F., Pagnotta P. et al. Acute anti-ischemic effect              of testosterone              in              men with
coronary artery disease // Am. J. Cardiol. - 1999. - Vol. 83. - P. 437-439.
English K.M., Steeds R.P., Diver M.J. et al. Low dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina // Circulation. - 2000. - Vol. 102. - P. 1906-1911.
Khaw K.T., Dowsett M., Folkerd E. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men. European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study // Circulation. - 2007. -
Vol. 116. - P. 2694-2701.
Laughlin G.A., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men // J. Clin. Endocrinol. Metab. -
- Vol. 93. - P. 68-75.